M&A Deal Summary

Idera Pharmaceuticals Acquires Aceragen

On September 28, 2022, Idera Pharmaceuticals acquired life science company Aceragen

Acquisition Highlights

This is Idera Pharmaceuticals’ 1st transaction in the Life Science sector.
This is Idera Pharmaceuticals’ 1st transaction in the United States.
This is Idera Pharmaceuticals’ 1st transaction in North Carolina.

M&A Deal Summary
Date	2022-09-28
Target	Aceragen
Sector	Life Science
Buyer(s)	Idera Pharmaceuticals
Deal Type	Add-on Acquisition
Advisor(s)	Wedbush Securities (Financial) Fenwick & West (Legal)

Target

Aceragen

Research Triangle Park, North Carolina, United States

Aceragen is a biopharmaceutical company developing innovative therapeutics for rare and orphan diseases. The Company is advancing ACG-801 (rhAC) as an investigational enzyme replacement therapy for the treatment of patients with Farber disease and potentially other diseases associated with the dysregulation of ceramide metabolism, including cystic fibrosis. Its other development lead is ACG-721, an oral small molecule candidate for cystic fibrosis pulmonary exacerbations and related orphan infectious diseases. Aceragen is based in Research Triangle Park, North Carolina.

Search 214,238 Deals Now

SEARCH BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Try Free

Buyer(S) 1

Buyer